ÂÜÀòÂÒÂ×

Alex Delbridge PhD is a seasoned professional in the biotechnology and pharmaceutical sectors, currently serving as a Senior Investment Associate at Omega Funds since August 2021. Concurrently, Alex holds Board Observer positions at BridgeBio Oncology Therapeutics, NRG Therapeutics, and Scorpion Therapeutics, contributing insights on governance and strategy. Previous experience includes consultancy at Putnam Associates, where guidance on commercial strategy was provided to leading pharmaceutical clients, along with postdoctoral research at Biogen focused on Multiple Sclerosis and Neuroimmunology. Alex's educational background includes a Ph.D. in Oncology and Cancer Biology from the University of Melbourne, alongside various business and leadership qualifications from prestigious institutions.